Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
IREN enters October with the lending market showing its first signs of genuine relief after a brutal September squeeze, yet short interest remains at 27.7% of free float and the stock is still sliding.
The most notable shift in the past week is in borrow availability. For most of September, availability was below 5%, touching a 52-week low of 0.35% on September 3rd, meaning the lending pool was almost entirely exhausted. That picture has changed. Availability climbed to 23.9% by October 5th, up from 8.1% the prior Thursday, a meaningful reopening of the pool. Borrow cost has also retreated, easing 7% on the week to 0.84%, its lowest level since early August. Those two moves together tell the same story: the acute squeeze pressure that defined September has receded. However, short interest itself is essentially unchanged over the past week, up just 0.6%, at 78.7 million shares. Bears covered heavily in September, reducing the position by 21% over 30 days, but that covering has now stalled. The ORTEX short score of 68.2 ranks in the 6th percentile of the universe, barely changed from the 68.3 reported last week. The easy covering appears to be done, and what remains is a committed short base that is no longer being squeezed out.
Options are not adding urgency to either side of the argument. The put/call ratio is 0.68, slightly below its 20-day average of 0.70 and a fraction under half a standard deviation from normal. There is no unusual hedging demand and no aggressive call buying. The options market is, for now, a quiet bystander.
The analyst register tells the more interesting story. JP Morgan made the sharpest move recently, flipping from Underweight to Overweight on September 14th and raising its target from $46 to $65, a significant directional shift from a bellwether firm. That followed two fresh initiations in mid-September: Northland at Outperform with a $99 target, and Rothschild at Neutral with a $40 target, roughly where the stock trades today. B. Riley trimmed its target from $96 to $91 on September 29th but kept its Buy rating. The resulting consensus picture is mostly bullish, with the mean price target at $77.69 against a current price of $40.48. That gap implies nearly 92% upside on the Street's central case, a figure that captures the tension between strong institutional conviction and persistent bearish positioning. The EPS momentum factor scores rank in the 98th to 100th percentile, and analyst recommendation divergence from consensus ranks 99th, both pointing to a setup where the Street sees a large gap between current price and fair value. The EV/EBITDA multiple at 3.6x has compressed 11% over 30 days, tracking the stock's decline.
The bull case rests on IREN's GPU-as-a-service pivot: sold-out 2026 capacity, roughly $4B of contracted ARR, multi-year agreements with major hyperscalers, and contract pricing that has risen sharply over the past year. Bears flag execution risk at the Sweetwater site, customer concentration, and the possibility that GPU rental markets soften as the fleet scales. The transition away from bitcoin mining is well advanced but not complete, and any slip in deployment timelines would hit numbers that already assume 104,000 average GPUs deployed in FY2027.
Institutional flows add a further layer. Citadel added 18.2 million shares as of September 23rd, bringing its stake to 4.7%. BlackRock added 8.9 million shares and State Street added 3.8 million, both as of September 30th. Goldman Sachs filed a 13G in August disclosing a 9.4% stake at that time, though that position is as-last-disclosed and may have changed. None of these filings carry activist intent; all are passive 13G registrations. The caveat applies throughout: 13D/G stakes are event-driven disclosures and holders can drop below 5% without a further filing.
The next earnings print is scheduled for November 6th, 31 days away. Past results have been unambiguous in one direction: the stock fell more than 8% on the day after each of the two most recent prints, before recovering over the following five days. With availability now looser and the short base stable rather than retreating, the setup into that print is less about a mechanical squeeze and more about whether the November numbers validate the $4B ARR narrative that underpins the Street's wide-open price targets.
See the live data behind this article on ORTEX.
Open IREN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
